EUVIMEDEUVIMED entdecken
Crossref

Efficacy of Antiseizure Medications in Wolf–Hirschhorn Syndrome

Ayumi Horiguchi iD, Reiko Koichihara, Kenjiro Kikuchi, Hazuki Nonoyama, Atsuro Daida iD, Daiju Oba, Yuko Hirata, Ryuki Matsuura iD, Hirofumi Ohashi, Shin-Ichiro Hamano

Neuropediatrics · 01.10.2023 · 54 (05) · 339-343

DOI: 10.1055/a-2077-1988 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuropediatrics, erschienen am 01.10.2023. Verfasst von Ayumi Horiguchi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurology, Saitama Children's Medical Center, Saitama, Saitama, Japan. Hauptthemen laut MEDLINE: Wolf-Hirschhorn Syndrome, Epilepsy, Status Epilepticus. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Wolf–Hirschhorn syndrome (WHS) is caused by deletion of the terminal region of chromosome 4 short arm and is frequently associated with intractable epilepsy. This article evaluates the clinical features of epileptic seizures in WHS and the therapeutic efficacy of oral antiseizure medications (ASMs). Patients with WHS who were treated for epilepsy at the Saitama Children's Medical Center under 5 years of age were included. WHS was diagnosed based on genetic tests and clinical symptoms. Medical records regarding the age of onset of epilepsy, seizure type, treatment of status epilepticus (SE), and effectiveness of ASMs were retrospectively reviewed. Oral ASMs were considered effective when seizures were reduced by at least 50% compared with the premedication level. Eleven patients were included in the study. The median age at the onset of epilepsy was 9 months (range: 5–32 months). Unknown-onset bilateral tonic-clonic seizure was the most common type of seizure, occurring in 10 patients. Focal clonic seizures occurred in four patients. Ten patients exhibited recurrent episodes of SE, and its frequency during infancy was monthly in eight patients and yearly in two. SE occurrence peaked at 1 year of age and decreased after 3 years of age. The most effective ASM was levetiracetam. Although WHS-associated epilepsy is intractable with frequent SE occurrence during infancy, improvement in seizure control is expected with age. Levetiracetam may be a novel ASM for WHS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Wolf-Hirschhorn SyndromeEpilepsyStatus EpilepticusHumansLevetiracetamRetrospective StudiesSeizuresAnticonvulsants

Substanzen

LevetiracetamAnticonvulsants

Autor:innen und Institutionen

  • Division of Neurology, Saitama Children's Medical Center, Saitama, Saitama, Japan.
  • Division of Medical Genetics, Saitama Children's Medical Center, Saitama, Saitama, Japan.

ORCID-Profile: Ayumi Horiguchi, Atsuro Daida, Ryuki Matsuura

Zitieren

APA

Horiguchi, A., Koichihara, R., Kikuchi, K., Nonoyama, H., Daida, A., Oba, D., Hirata, Y., Matsuura, R., Ohashi, H., & Hamano, S. I. (2023). Efficacy of Antiseizure Medications in Wolf–Hirschhorn Syndrome. Neuropediatrics, 54(05), 339-343. https://doi.org/10.1055/a-2077-1988

Vancouver

Horiguchi A, Koichihara R, Kikuchi K, Nonoyama H, Daida A, Oba D, et al. Efficacy of Antiseizure Medications in Wolf–Hirschhorn Syndrome. Neuropediatrics. 2023;54(05):339-343. doi:10.1055/a-2077-1988

BibTeX
@article{Horiguchi2023,
  author = {Horiguchi, Ayumi and Koichihara, Reiko and Kikuchi, Kenjiro and Nonoyama, Hazuki and Daida, Atsuro and Oba, Daiju and Hirata, Yuko and Matsuura, Ryuki and Ohashi, Hirofumi and Hamano, Shin-Ichiro},
  title = {Efficacy of Antiseizure Medications in Wolf–Hirschhorn Syndrome},
  journal = {Neuropediatrics},
  year = {2023},
  volume = {54},
  number = {05},
  pages = {339--343},
  doi = {10.1055/a-2077-1988}
}
Kostenlos starten →